Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.
about
Cirrhotic cardiomyopathyCirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patientsRecent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapiesInterpretation and use of natriuretic peptides in non-congestive heart failure settingsPlasma Long Noncoding RNA Urothelial Carcinoma Associated 1 Predicts Poor Prognosis in Chronic Heart Failure Patients.Cirrhotic Cardiomyopathy: A New Clinical Phenotype.NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis.Arrhythmia risk in liver cirrhosis.ProBNP-derived peptides in cardiac disease.Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis.The end-organ impairment in liver cirrhosis: appointments for critical care.New insight into the role of NT-proBNP in alcoholic liver cirrhosis as a noninvasive marker of esophageal varicesImmune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications.Liver cirrhosis and arterial hypertension.Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation.Heart rhythm turbulence and NT-proBNP in decompensated liver cirrhosis--a pilot study.Evaluation of cardiac functions of cirrhotic children using serum brain natriuretic peptide and tissue Doppler imaging.Brain Natriuretic Peptide in Liver Cirrhosis and Fatty Liver: Correlation with Cardiac Performance.Physiology and clinical significance of natriuretic hormonesN-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patientsDiagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP).Clinical relevance of non-cardiac determinants of natriuretic peptide levels.Cardiac and systemic haemodynamic complications of liver cirrhosis.The heart and the liver.N-terminal pro-brain natriuretic peptide level as a screening tool for cardiac involvement in paediatric diseases of extracardiac origin.QT interval prolongation in liver cirrhosis: innocent bystander or serious threat?Review on natriuretic peptides: where we are, where we are going.Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.Cirrhotic cardiomyopathy: pathogenesis and clinical relevance.Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspectsRecent advances in cirrhotic cardiomyopathy.Cirrhotic Multiorgan Syndrome.Natriuretic peptides: Diagnostic and therapeutic use.NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis.Brain type natriuretic peptide (BNP)-A marker of new millennium in diagnosis of congestive heart failure.Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients.Origins of cardiac dysfunction in cirrhosis.Short-term cardiac and noncardiac mortality following liver transplantation.
P2860
Q26778048-D1ED84FE-1D0F-4EBF-AFD0-CD78D376CF7BQ26826868-BAD3AE7C-3813-4A73-B6D6-9A1CCF7EDAEFQ27002436-820256F3-60E4-4CB8-BF5E-839D5B59ED5CQ33670478-7AD03387-61ED-414B-825A-B469B00FA9F8Q33703155-C97B9C18-5BBA-4C98-83CB-D7E69C13110DQ33848796-EC299C32-4E9F-45A4-8388-4CF924CA73C6Q34934407-CAE9D206-59C7-4634-81A9-8E6C9EC8AA4FQ35308671-01E23D8D-77F6-4D60-A31B-7FDFDF5E5929Q35847164-6A241ECE-3C92-451D-B747-2C16FBD12A0CQ35873829-6E9531D4-426E-42D4-9046-5F450ADA6D79Q35888758-E8366CB3-E06A-4570-B4C6-930271A139D7Q35993701-6A31861A-8D5E-4CEA-AAEA-6625F7157748Q36193124-395E1665-57B0-49A0-9E92-80FB9BDBE828Q36219910-92177BF5-23A7-4437-92E9-7EBF9A993983Q36350919-D3FAEEB5-6DCA-4718-9F20-4CFFD244521AQ36415436-F062D7F0-FDC3-4E4F-9FC9-CB6403818ED7Q36514049-41392397-E673-4D65-8E01-7799B00834B9Q36516487-61C5EECB-14E5-4655-9D9F-C77F8A45B0E7Q36662684-0608CEF9-5F69-4B9D-9C94-8DAD0089EDA5Q36766666-578A2EA0-007A-4AAD-A63F-C4128AFDB68CQ36862282-7390BEAE-A9C9-4A0A-AF00-241A9DF708E0Q37040910-8DD9C4D5-BE54-4E0B-8B8B-92D878754845Q37253670-D95F1251-D516-4443-ABDC-F93224A46B86Q37326739-F42DFF2C-CEEE-44B7-AAAC-CCEFEB80B273Q37368987-60DDA303-5650-42D1-9092-12F1C1B12B62Q37390649-46911FE9-6150-423E-BCE0-3C0FEAB61F53Q37864597-61991405-C267-496E-AD85-22CAD80F378BQ37965681-0ACB9CA9-8791-4643-9477-8F80A7766BF5Q38089931-74555768-0B3C-4FED-A393-C7A7A19BAC1DQ38133308-F441ED41-473C-43BD-8AB8-A60BA2C1B496Q38161771-00104D35-7F3C-4A88-8B9C-5B5B13AB1734Q38268612-7A2CD4DF-4949-4471-8E45-26F0121361B9Q38268965-F40F4B0E-1916-4E90-97EF-57FE1B611DC5Q38538183-61F5BC53-1DB7-4532-9207-28E223ACBEB6Q39581832-2B0CF7E4-5937-4273-8470-9B4DA8A974D4Q39660987-B073A9BF-DD86-4007-8674-A0ADB9AB7E09Q40238774-9F177424-BD7B-4B62-AD0D-AD71AD519397Q41738514-F3E3133A-D9F1-4052-9C9F-36008027625AQ41914715-0928A1DB-0509-40F2-BBB5-7E0AC404EEB5Q41991424-3B9ECB51-07E4-4AB8-8E70-0358F14564DB
P2860
Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Increased circulating pro-brai ...... ction and severity of disease.
@ast
Increased circulating pro-brai ...... ction and severity of disease.
@en
type
label
Increased circulating pro-brai ...... ction and severity of disease.
@ast
Increased circulating pro-brai ...... ction and severity of disease.
@en
prefLabel
Increased circulating pro-brai ...... ction and severity of disease.
@ast
Increased circulating pro-brai ...... ction and severity of disease.
@en
P2093
P2860
P356
P1433
P1476
Increased circulating pro-brai ...... nction and severity of disease
@en
P2093
E Christensen
F Bendtsen
J H Henriksen
S Fuglsang
P2860
P304
P356
10.1136/GUT.52.10.1511
P407
P50
P577
2003-10-01T00:00:00Z